Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Evaluation of Cancer-Specific Imaging Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy

NCT01227642 is registered in ClinicalTrials.gov with Beth Israel Medical Center as lead sponsor.

NCT NCT01227642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01227642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Evaluation of Cancer-Specific Imaging Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Lead sponsor
Beth Israel Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2007
Completion date
August 31, 2014
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage t2b or less of prostate cancer, prostate brachytherapy, transrectal prostate ultrasound treatment planning